Drugs / Lulizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03058822 | Jan → Mar 2017 | — | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT04903054 | Jan → Sep 2022 | disease related to solid organ transplantation | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lulizumab | “Pharmacokinetics of Lulizumab (BMS-931699) From Prefilled Syringe” NCT03058822 ↗ |
| Known as | BMS-931699 | “Pharmacokinetics of Lulizumab (BMS-931699) From Prefilled Syringe” NCT03058822 ↗ |
| Action | Inhibit | “Selective CD28 Blockade With Lulizumab” NCT04903054 ↗ |
| Route | Subcutaneous | “Method of administration: subcutaneously” NCT04903054 ↗ |
| Target | CD28 | “specific for human cluster of differentiation CD28” NCT04903054 ↗ |